Chugai Pharmaceutical Co., Ltd. (TYO:4519)

Chugai Pharmaceutical Revenue

Chugai Pharmaceutical had revenue of 404.74B JPY in the quarter ending September 30, 2026, with 21.48% growth. This brings the company's total for the last twelve months to 1.41T, up 16.53% year-over-year. In the year 2025, Chugai Pharmaceutical had annual revenue of 1.26T with 7.46% growth. That makes Chugai Pharmaceutical the 1,638th largest company in the world by revenue and 156th in Japan.

• Revenue (ttm): 1.41T
• Revenue Growth: +16.53%
• P/S Ratio: 7.91
• Revenue / Employee: 277.11M
• Employees: 5,104
• Market Cap: 11.34T

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Overseas 605.40B 48.1%
• Domestic Oncology 246.50B 19.6%
• Domestic Specialty 225.80B 18.0%
• Royalties and Other Operating Income 180.10B 14.3%

By Geography

• Overseas 605.44B 48.1%
• Japan 472.37B 37.6%
• Unallocated 180.14B 14.3%

Fiscal year ended Dec 31, 2025 See the full Chugai Pharmaceutical breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.26T	87.33B	7.46%
Dec 31, 2024	1.17T	59.24B	5.33%
Dec 31, 2023	1.11T	-148.58B	-11.79%
Dec 31, 2022	1.26T	260.19B	26.02%
Dec 31, 2021	999.76B	212.81B	27.04%

Data Sources: S&P Global Market Intelligence and Fiscal.ai Last updated: Oct 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company. Revenue segment data is provided by Fiscal.ai.

Update frequency:

Quarterly

Last checked:

Nov 2, 2026

Data Sources Report a data error